Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
Document Type
Presentation
Publication Date
11-8-2022
Keywords
oregon; portland; chiles
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Comments
Sanborn R, Gabrail N, Carneiro B, O'Hara M, Bordoni R, Gordon M, Khalil D, Hauke R, Taglienti C, Rogalski M, Styles R, Alvarado D, Maurer D, Crew L, Keler T, Yellin M. SITC Annual Meeting; November 8-12; Boston, MA. 2022;10(Suppl 2): 596. doi: 10.1136/jitc-2022-SITC2022.0596.